Komentarz do badania JUPITER Komentarz
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2008
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grodzicki , T., & Strach , M. (2008). Komentarz do badania JUPITER . Kardiologia W Praktyce, 2(4), 168-169. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1675
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615-22.
2. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-58.
3. Pearson T.A., Mensah G.A., Alexander R.W. et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499.
4. Albert M.A., Glynn R.J., Ridker P.M.: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003, 108: 161-167.
2. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-58.
3. Pearson T.A., Mensah G.A., Alexander R.W. et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499.
4. Albert M.A., Glynn R.J., Ridker P.M.: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003, 108: 161-167.